Cipla , one of India’s largest drugmakers by revenue, reported a bigger-than-expected 39.2% fall in first-quarter profit, its third consecutive quarterly decline, as muted sales of generic cancer drugs and supply disruptions affecting lanreotide, a treatment for rare tumors, weighed on its U.S. business.
